JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2003; 42:1188-1195, doi:10.1016/S0735-1097(03)00944-6
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, A. W.

ARTICLE

Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival

Results from the do tirofiban and reoprogive similar efficacy outcome trial (TARGET)

Albert W. Chan, MD*, David J. Moliterno, MD{dagger},*, Peter B. Berger, MD{ddagger}, Gregg W. Stone, MD§, Peter M. DiBattiste, MD||, Steven L. Yakubov, MD, Shelly K. Sapp, MS#, Kathy Wolski, MPH#, Deepak L. Bhatt, MD{dagger}, Eric J. Topol, MD{dagger} TARGET Investigators**

* Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
{dagger} Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
{ddagger} Division of Cardiology, Mayo Clinic Foundation, Rochester, Minnesota, USA
§ Lenox Hill Heart and Vascular Institute, New York, New York, USA
|| Merck, West Point, Pennsylvania, USA
Riverside Methodist Hospital, Columbus, Ohio, USA
# Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Manuscript received December 12, 2002; revised manuscript received April 22, 2003, accepted May 9, 2003.

* Reprint requests and correspondence: Dr. David J. Moliterno, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195.
molited{at}ccf.org

OBJECTIVES: We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor.

BACKGROUND: Antiplatelet therapy plays a pivotal role in contemporary percutaneous coronary interventions (PCI).

METHODS: Outcomes among 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared according to whether they received 300 mg of clopidogrel before PCI (93.1%) versus immediately after the procedure.

RESULTS: The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6.6% vs. 10.4%, p = 0.009), mainly because of reduction of MI (6.0% vs. 9.5%, p = 0.012). The benefit of clopidogrel pretreatment was sustained at six months (death, MI, any TVR: 14.6% vs. 19.8%, HR = 0.71, p = 0.010), and this was due mainly to lowering of death and MI (7.8% vs. 13.0%, p = 0.001). At one year, clopidogrel pretreatment was associated with a lower mortality rate (1.7% vs. 3.6%, p = 0.011). Because clopidogrel pretreatment was not randomized, multivariable and propensity analyses were performed. After adjusting for baseline heterogeneity, clopidogrel pretreatment was an independent predictor for death or MI at 30 days (HR = 0.63, p = 0.012) and at six months (HR = 0.61, p = 0.003), and survival at one year (HR = 0.53, p = 0.044). No excess in 30-day bleeding events was noted with clopidogrel pretreatment.

CONCLUSIONS: Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa inhibitor, clopidogrel pretreatment is associated with a reduction of death and MI irrespective of the type of GP IIb/IIIa inhibitor used.

Abbreviations and Acronyms
  ACS = acute coronary syndrome
  ADP = adenosine diphosphate
  CREDO = Clopidogrel for Reduction of Events During Observation
  EPISTENT = Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
  GOLD = Assessing Ultegra-AU Study
  GP = glycoprotein
  MI = myocardial infarction
  PCI = percutaneous coronary intervention
  PCI-CURE = PCI substudy of the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
  TIMI = Thrombolysis In Myocardial Infarction
  TVR = target vessel revascularization




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
J. Nappi
Benefits and limitations of current antiplatelet therapies
Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S5 - S10.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
F.-J. Neumann, A. Kastrati, and G. Schwarzer
New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective
Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A4 - A10.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O. F. Bertrand, R. De Larochelliere, J. Rodes-Cabau, G. Proulx, O. Gleeton, C. Manh Nguyen, J.-P. Dery, G. Barbeau, B. Noel, E. Larose, et al.
A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation
Circulation, December 12, 2006; 114(24): 2636 - 2643.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. B. Borden and D. P. Faxon
Facilitated Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1120 - 1128.
[Abstract] [Full Text] [PDF]


Home page
VASC ENDOVASCULAR SURGHome page
R. A. Chaer, J. A. Graham, and L. Mureebe
Platelet Function and Pharmacologic Inhibition
Vascular and Endovascular Surgery, August 1, 2006; 40(4): 261 - 267.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Steinhubl, P. B. Berger, D. M. Brennan, E. J. Topol, and for the CREDO Investigators
Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., March 7, 2006; 47(5): 939 - 943.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
K D Dawkins, T Gershlick, M de Belder, A Chauhan, G Venn, P Schofield, D Smith, J Watkins, H H Gray, and Joint Working Group on Percutaneous Coronary Inter
Percutaneous coronary intervention: recommendations for good practice and training
Heart, December 1, 2005; 91(suppl_6): vi1 - vi27.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. J. Moliterno and S. R. Steinhubl
Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both?
JAMA, September 14, 2005; 294(10): 1271 - 1273.
[Full Text] [PDF]


Home page
JAMAHome page
M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, B. S. Lewis, S. A. Murphy, C. H. McCabe, E. Braunwald, et al.
Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study
JAMA, September 14, 2005; 294(10): 1224 - 1232.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non--ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
I. Hunt, L. J.H. Blows, and S. J. Patel
Why clopidogrel failed to inhibit platelet function early after coronary artery bypass surgery: To load or not to load, and is it a question of resistance?
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1197 - 1197.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. L Longstreth and J. R Wertz
High-Dose Clopidogrel Loading in Percutaneous Coronary Intervention
Ann. Pharmacother., May 1, 2005; 39(5): 918 - 922.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio
Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study
Circulation, April 26, 2005; 111(16): 2099 - 2106.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J., April 2, 2005; 26(8): 804 - 847.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial
J. Am. Coll. Cardiol., July 7, 2004; 44(1): 14 - 19.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. van der Heijden, I. C. D. Westendorp, R. K. Riezebos, F. Kiemeneij, T. Slagboom, L. R. van der Wieken, and G.-J. Laarman
Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation
J. Am. Coll. Cardiol., July 7, 2004; 44(1): 20 - 24.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. Rozenman
For how long should treatment with clopidogrel be continued after coronary stent implantation?
J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1331 - 1331.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.-H. Chen, P.-Y. Lee, W. Ng, H.-F. Tse, and C.-P. Lau
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment
J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1122 - 1126.
[Abstract] [Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
More Support for Clopidogrel Before PCI
Journal Watch Cardiology, December 12, 2003; 2003(1212): 4 - 4.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.